How to Get Wegovy Without Insurance in 2026
Wegovy's list price is $1,349 per month - but you almost never pay that. Below are the legitimate cash-pay paths that bring it down to roughly $249–$349/month in July 2026, ranked by typical cost.
Cash-pay Wegovy paths at a glance
| Path | Monthly | Annual |
|---|---|---|
| Wegovy savings card (with commercial insurance) | $0–$25 | $0–$300 |
| Compounded semaglutide via telehealth | $249 | $2,988 |
| NovoCare manufacturer self-pay | $349 | $4,188 |
| Branded Wegovy via telehealth | $329 | $3,948 |
| Cash retail (full WAC) | $1,349 | $16,188 |
1. Wegovy Savings Card (if you have commercial insurance)
If your commercial insurance already covers Wegovy, the manufacturer savings card from Novo Nordisk can drop your copay to as low as $0 to $25 per month. This is by far the cheapest legitimate option, but it requires you to already have coverage. Apply directly at novocare.com. Full breakdown of eligibility, limits, and the government-insurance exclusion on the Wegovy Coupon page.
Government insurance - Medicare, Medicaid, Tricare, VA - is excluded from manufacturer copay programs by federal anti-kickback rules.
2. Compounded semaglutide (~$249/mo, narrow eligibility)
Legal availability narrowed sharply once the FDA closed the shortage-based exemption that fueled 2023-2024 telehealth compounding - only patients with a documented individual clinical need (non-standard dose, allergy) now qualify under a 503A pharmacy's individual-patient exception; cost savings alone does not. Where still available, pricing runs around $249/mo. See the full compounded GLP-1 regulatory timeline and pharmacy-verification checklist before ordering.
3. NovoCare manufacturer self-pay (~$349/mo)
NovoCare is Novo Nordisk's direct-to-patient program. It is the closest Wegovy equivalent of LillyDirect (which is for Eli Lilly drugs like Zepbound and Mounjaro). The NovoCare self-pay reference price for Wegovy is approximately $349 per month as of July 2026.
Eligibility is income-based and program details change. Apply at novocare.com.
Visit NovoCare →4. Branded Wegovy via telehealth (~$329/mo)
If NovoCare self-pay is not available to you, branded Wegovy through a telehealth platform typically runs around $329 per month and includes the prescriber visit and shipment. The trade-off vs NovoCare is the monthly subscription markup; the upside is faster onboarding (often 1–3 days to a prescription).
Major options as of July 2026:
Affiliate partners listed below - your price does not change.
- Hims & Hers - largest telehealth GLP-1 platform by revenue
- Ro - bundled Body Program with coaching
- Lemonaid Health - pay per visit, not subscription
- LifeMD - Novo Nordisk direct partnership
See our full telehealth provider comparison for side-by-side pricing, drug menu, and speed-to-Rx.
5. Switch to Zepbound (often cheaper per pound lost)
Zepbound (tirzepatide, made by Eli Lilly) reaches a higher peak weight loss in trial data - ~22.5% in SURMOUNT-1 vs Wegovy's ~14.9% in STEP-1 - and Eli Lilly's LillyDirect program offers self-pay vials starting around $299/month for 2.5 mg (and $399/month for 5 mg). For many cash-pay patients, Zepbound ends up cheaper per pound lost even though the monthly sticker can be similar.
Run the comparison directly on Wegovy vs Zepbound, the Zepbound without-insurance guide, or use the cheapest GLP-1 finder to see your exact $/lb breakdown. The molecule-level tirzepatide cost overview covers Mounjaro, Zepbound, and compounded options in one place.
Bonus: oral Wegovy 25 mg (~$149/mo)
FDA-approved in early 2026, oral Wegovy 25 mg is the same molecule as the injection in tablet form. NovoCare self-pay pricing is the same as the injection (~$149/month). The downside is strict fasting requirements (empty stomach, 30-minute wait before food) and slightly lower trial efficacy (13.6% peak weight loss in OASIS-4 vs 14.9% in STEP-1). The upside is no needles.
Full details on the oral Wegovy page.
Frequently asked questions
How much does Wegovy cost without insurance in 2026?
Without insurance, the practical cheapest legal path to Wegovy in July 2026 is NovoCare direct self-pay at $349/mo standard - and Novo's current promotional pricing drops that to $199 for the first two months at the 0.25 and 0.5 mg starter doses through December 31, 2026. Telehealth platforms (Hims, Ro, LifeMD) charge that same NovoCare drug price plus their own separate membership fee (commonly $39 the first month, then roughly $74-149/mo) - so going through a platform costs more than ordering direct, not less; the fee buys the integrated prescriber visit. Compounded semaglutide is a narrow fallback since the FDA closed the shortage-based supply pipeline in 2024-2025 - some licensed 503A pharmacies still fill on a case-by-case basis. Plan on Wegovy specifically (not Ozempic) because NovoCare's cash-pay pricing structure runs through the weight-loss brand, and STEP-1's 14.9% peak-weight-loss endpoint takes 68 weeks of consistent dosing to reach.
What is NovoCare and how do I qualify?
NovoCare is Novo Nordisk's patient-assistance program for branded GLP-1s including Wegovy. The current NovoCare self-pay reference price is around $349 per month. Eligibility depends on income and insurance status; you apply through NovoCare directly. Even patients with commercial insurance can sometimes use the savings card to drop their copay to as little as $0, depending on plan rules.
Is the Wegovy savings card the same as NovoCare?
No - they are two different programs from Novo Nordisk. The Wegovy savings card is for patients whose commercial insurance already covers Wegovy and reduces the copay (often to $0–$25). NovoCare is the broader self-pay/patient-assistance pathway for patients without coverage. Government insurance (Medicare, Medicaid, Tricare, VA) is excluded from both programs by federal anti-kickback rules.
Is compounded semaglutide still available in 2026?
For Wegovy specifically, compounded semaglutide is a narrow fallback rather than a mainstream cash-pay path. After the FDA officially declared the semaglutide shortage resolved in early 2025, the §503A "shortage exemption" that allowed mass telehealth compounding disappeared. Personalized compounded semaglutide is still legally produced by licensed 503A pharmacies for an individual patient on a documented clinical need - a non-standard dose, an excipient allergy, or a prescriber-specified formulation - but the "any-patient, any-dose, $249/mo" model that defined 2023-2024 is over. If a telehealth platform is advertising unrestricted compounded semaglutide as a routine offering in July 2026, verify the pharmacy's PCAB accreditation and state license before ordering; treat US-sourced human-grade product as the only legitimate route (avoid "research peptide" resellers - those are not legal for human use).
What about the new oral Wegovy 25 mg?
The FDA approved oral semaglutide 25 mg for chronic weight management in early 2026. It is the same molecule as injectable Wegovy in tablet form. NovoCare self-pay for the oral version starts around $149 per month - the same as the injection. The downside is strict fasting requirements (take on an empty stomach, no food for 30 minutes after) and a slightly lower trial efficacy (13.6% vs 14.9% peak weight loss).
Can I use a GoodRx coupon for Wegovy?
GoodRx coupons rarely beat NovoCare self-pay or telehealth pricing for Wegovy specifically, because Wegovy is a brand-name drug under patent and there is no generic. GoodRx is more useful for older GLP-1s with generic equivalents, or for the consultation cost (GoodRx Care subscription, $39/month, plus whatever the pharmacy charges).
Should I just switch to Zepbound or another GLP-1?
It is worth running the math. Zepbound (tirzepatide) has both higher trial efficacy (22.5% peak weight loss) and a lower self-pay floor through LillyDirect for some doses. If your insurance covers neither Wegovy nor Zepbound, you may end up paying less per pound lost on Zepbound. The /cheapest-glp1 and /wegovy-vs-zepbound-guide pages run those comparisons head to head.
Wegovy coverage by major insurer
Coverage stance and per-carrier details for Wegovy. Each link goes to the full prior-auth requirements, cost table, and appeal playbook for that carrier.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.